Skip to main content
. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212

Figure 2.

Figure 2

Progression free and overall survival.

(A) Progression-free survival (PFS) in the intention-to-treat (ITT) analysis set. (B) PFS in the ITT analysis set that was clustered according to the pegylated liposomal doxorubicin (PLD) dose administration: 30 mg/m2 (PLD30) and 40 mg/m2 (PLD40). (C) Overall survival (OS) in the ITT analysis set. (D) PFS in the pegylated liposomal doxorubicin (PLD) + olaparib (per-protocol [PP]) analysis set. (E) OS in the PP analysis set.

CI, confidence interval; HR, hazards ratio.